Evaluation of Prednisolone and SPI-62 in the Management of Polymyalgia Rheumatica: A Randomized Controlled Trial

The primary objective of this clinical trial is to evaluate the efficacy of **prednisolone** in combination with SPI-62 in participants diagnosed with **polymyalgia rheumatica** (PMR). This study aims to determine whether the combination therapy can provide improved management of PMR symptoms compared to standard treatment. The clinical relevance of this objective lies in the potential to enhance therapeutic outcomes for patients suffering from this inflammatory disorder, which is characterized by muscle pain and stiffness, particularly in the shoulders and hips. No secondary objectives are specified for this trial.

The clinical trial involves participants diagnosed with **polymyalgia rheumatica**. The study population includes both male and female subjects, with an age range that encompasses adults and older adults. The trial population selection criteria and the total number of participants have not been disclosed by the sponsor. The study includes a vulnerable population, although specific lifestyle considerations such as diet, physical activity, or habits have not been detailed. The sponsor has not provided information regarding key inclusion or exclusion criteria for this trial.

The clinical trial is designed to evaluate the efficacy and safety of **prednisolone** in combination with SPI-62 in participants diagnosed with **polymyalgia rheumatica**. This study is structured as a Phase 3, randomized, double-blind, controlled trial. The estimated recruitment start date is December 1, 2023, with an anticipated completion date of September 30, 2024. The trial will involve multiple study visits, beginning with an inclusion visit to screen potential participants for eligibility based on predefined criteria. Following successful screening, participants will be randomly assigned to receive either the investigational treatment or a control, with neither the participants nor the investigators aware of the group assignments to maintain blinding.

Participants will be required to attend regular follow-up visits throughout the study duration to monitor their response to treatment and assess any adverse events. These visits will include clinical assessments, laboratory tests, and completion of questionnaires to evaluate the impact of the treatment on disease symptoms and quality of life. The end-of-study visit will occur at the conclusion of the treatment period, where final evaluations will be conducted to gather comprehensive data on the primary and secondary endpoints of the trial.

The expected length of participant involvement in the study is approximately 10 months, from the initial screening to the end-of-study visit. Participants may be withdrawn from the study early if they experience significant adverse effects, fail to comply with study procedures, or if the investigator deems it in the participant's best interest. The trial is conducted in accordance with ethical guidelines and regulatory requirements to ensure the safety and well-being of all participants.

The clinical trial documentation does not provide specific details regarding the experimental medication, including its name, pharmaceutical form, dosage, route, or frequency of administration. As such, no detailed description of the experimental treatment can be provided based on the available data.

Similarly, there is no information available about any non-experimental treatments used in the study, such as standard-of-care therapy, placebo, or comparator treatment. Consequently, no description of these treatments can be included.

Additional relevant information about drug administration, dosing schedules, and participant compliance monitoring is also not provided in the source data. Therefore, no further details can be offered regarding these aspects of the clinical trial.

The clinical trial is designed to assess efficacy in a Phase 3 study. The trial is scheduled to commence recruitment on December 1, 2023, with an estimated completion date of September 30, 2024. The efficacy assessment will be conducted using predefined parameters, although specific endpoints and methods for measuring efficacy are not detailed in the available data. The trial will follow a structured timeline to ensure systematic data collection and analysis. The study will adhere to rigorous standards typical of Phase 3 trials, focusing on evaluating the treatment's effectiveness in a larger patient population. The trial's design and execution will align with established clinical protocols to ensure the reliability and validity of the efficacy outcomes.